




Rhenium-186 HEDP

Revised: December 3, 2018.

CASRN: 140709-07-5



Drug Levels and Effects

Summary of Use during Lactation

Information in this record refers to the use of rhenium-186 HEDP (rhenium-186 etidronate) as a therapeutic agent. No information is available on the therapeutic use of rhenium HEDP during breastfeeding. Because strontium can substitute for calcium in infant bones, the manufacturer and expert opinion recommend discontinuing breastfeeding before a nursing mother receives rhenium HEDP.[1]

Drug Levels

Rhenium 186 emits a beta particle with a mean energy of 0.349 MeV and gamma emission with a 0.137 MeV photo peak. Its physical half-life is 3.7 days.[1]

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Bodei L, Lam M, Chiesa C et al. EANM procedure guideline for treatment of refractory metastatic bone pain. *Eur J Nucl Med Mol Imaging*. 2008;35:1934-40. PubMed PMID: 18649080.

Substance Identification

Substance Name

Rhenium-186 HEDP

CAS Registry Number

140709-07-5

Drug Class

Breast Feeding

Lactation

Radiopharmaceuticals

Etidronic Acid